Researchers led by Donald Ingber and Lorenzo Ferri have developed an advanced organ chip platform that integrates patient-derived organoids with elements of the tumor microenvironment to predict chemotherapy responses in esophageal adenocarcinoma. This novel model addresses limitations of conventional organoids by incorporating stromal components, enhancing the physiological relevance of drug testing. The platform aims to guide personalized neoadjuvant chemotherapy decisions and improve survival rates in a cancer type characterized by high mortality and common chemoresistance.